Since its founding in mid-2018, Bold Therapeutics has made rapid and efficient progress. Today, Bold Therapeutics’ BOLD-100 advances into a global Phase 2 trial in the treatment of advanced GI… Read More
VANCOUVER, B.C. — NervGen Pharma Corp. (TSX-V: NGEN; OTCQX: NGENF) (“NervGen” or the “Company”), a clinical stage biotech company dedicated to developing innovative solutions for the treatment of nervous system damage, today… Read More
Takeda Canada’s Rethinking Rare campaign puts a spotlight on the rare disease community TORONTO — Today marks Rare Disease Day. Takeda Canada is proud to recognize this global initiative to promote equity… Read More
In this Phase 3 trial, Dupixent added to standard-of-care antihistamines nearly doubled reduction in itch and urticaria activity scores compared to standard-of-care alone at 24 weeks in biologic-naïve patients uncontrolled… Read More
Late-breaking data at 2022 AAAAI Annual Meeting show Dupixent® (dupilumab) significantly improved signs and symptoms of eosinophilic esophagitis Dupixent 300 mg weekly is the only biologic medicine to show positive, clinically meaningful Phase 3 results… Read More
